Literature DB >> 10773256

Chronological changes in MRI findings of spinal dural arteriovenous fistula.

T Horikoshi1, K Hida, Y Iwasaki, H Abe, M Akino.   

Abstract

BACKGROUND: Intramedullary high-intensity changes on T2-weighted magnetic resonance images (MRI) occur in patients with spinal dural arteriovenous fistulas (AVF). Reduction of the high-intensity area after treatment has been noted; however, there are still questions about whether the change is related to preoperative clinical grade, postoperative improvement, or efficacy of treatment. This study tried to clarify the relationship between chronological changes in the high intensity area with the treatment and clinical course.
METHODS: Chronological changes in an intramedullary high-intensity area after surgery were retrospectively analyzed in recent 13 patients with spinal dural AVFs who were treated and followed by MRI.
RESULTS: Preoperative intramedullary high-intensity areas were observed on T2-weighted images in all cases. The extent of the high-intensity area correlated with preoperative neurological deficits. The intramedullary high-intensity area was reduced or diminished after successful interruption of AVFs. The high-intensity area started to decrease within 1 to 4 months after treatment in all patients, and disappeared at 2 weeks to 23 months in seven patients. The reduction may suggest interruption of the fistula and improvement of venous circulation, but was not always correlated to clinical improvement. The intramedullary high-intensity areas rapidly disappeared in two patients, but did not clearly correspond to the clinical improvement.
CONCLUSIONS: The time course of postoperative MRI changes is helpful for evaluating the efficacy of treatment after surgery for spinal dural AVFs.

Entities:  

Mesh:

Year:  2000        PMID: 10773256     DOI: 10.1016/s0090-3019(99)00168-8

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  7 in total

1.  The use of magnetic resonance imaging in predicting the clinical outcome of spinal arteriovenous fistula.

Authors:  Dong Ah Shin; Keun Young Park; Gyu Yeul Ji; Seong Yi; Yoon Ha; Seoung Woo Park; Do Heum Yoon; Keung Nyun Kim
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

2.  First-Pass Contrast-Enhanced MR Angiography in Evaluation of Treated Spinal Arteriovenous Fistulas: Is Catheter Angiography Necessary?

Authors:  S Mathur; S P Symons; T J Huynh; T R Marotta; R I Aviv; A Bharatha
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-03       Impact factor: 3.825

3.  Acute neurological deterioration after surgical interruption of spinal dural arteriovenous fistulas: clinical characteristics, possible predictors, and treatment. Patient series.

Authors:  Akihiko Saito; Naoki Yajima; Kimihiko Nakamura; Yukihiko Fujii
Journal:  J Neurosurg Case Lessons       Date:  2021-12-20

4.  Perfusion-weighted MRI of spinal dural arteriovenous fistula.

Authors:  K Yanaka; Y Matsumaru; K Uemura; A Matsumura; I Anno; T Nose
Journal:  Neuroradiology       Date:  2003-09-06       Impact factor: 2.804

5.  Spinal cord swelling with abnormal gadolinium-enhancement mimicking intramedullary tumors in cervical spondylosis patients: Three case reports and review of the literature.

Authors:  Toru Sasamori; Kazutoshi Hida; Shunsuke Yano; Aoyama Takeshi; Yoshinobu Iwasaki
Journal:  Asian J Neurosurg       Date:  2010-07

6.  Long-term outcomes and prognostic factors in patients with treated spinal dural arteriovenous fistulas: a prospective cohort study.

Authors:  Chengbin Yang; Yongjie Ma; An Tian; Jiaxing Yu; Sichang Chen; Chao Peng; Kun Yang; Guilin Li; Chuan He; Ming Ye; Tao Hong; Lisong Bian; Zhichao Wang; Feng Ling; Hongqi Zhang
Journal:  BMJ Open       Date:  2022-01-03       Impact factor: 2.692

7.  Clinical outcomes and prognostic factors in patients with spinal dural arteriovenous fistulas : a prospective cohort study in two Chinese centres.

Authors:  Yongjie Ma; Sichang Chen; Chao Peng; Chunxiu Wang; Guilin Li; Chuan He; Ming Ye; Tao Hong; Lisong Bian; Jiang Liu; Zhichao Wang; Adnan I Qureshi; Feng Ling; Hongqi Zhang
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.